EU rejects antidepressant health concerns raised by study
This article was originally published in Scrip
No public health concerns have been identified by recent publicised research about the use of antidepressants, the EU's CHMP has said, refuting claims made earlier this year in a widely publicised study.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.